FIMA

PCI Biotech is a clinical-stage biopharmaceutical company focused on developing innovative therapies through its proprietary photochemical internalisation (PCI) technology, branded as fima. The fima platform is designed to enhance the intracellular delivery of therapeutic molecules, such as small molecules, vaccines, and nucleic acids, by triggering their release from endosomes using light. The company's lead program, fimaCHEM, targets bile duct cancer (cholangiocarcinoma) and has reached pivotal clinical trials. Additionally, the fimaVACC and fimaNAZ programs aim to improve the efficacy of vaccines and nucleic acid-based therapies, respectively. PCI Biotech operates primarily in the oncology and immunology sectors, leveraging its unique delivery mechanism to address unmet medical needs.